Bristol Myers Squibb (BMY): return calculator
Bristol Myers Squibb (BMY) shares, a US pharmaceutical company strong in oncology, listed in New York.
Updated
- Type
- Stocks
- Market
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Data range
- 2016-07 – 2026-06 · 10 years
- Source
- Yahoo Finance
US$1,000 invested 9 years ago would be worth today
US$1,373
+37.3% total return
Try your own values in the calculators below.
Return calculator
Pick an amount and a period to see what an investment in Bristol Myers Squibb (BMY) would be worth today. By default we include reinvested dividends (total return).
Lump sum
What a one-off investment would be worth today.
Monthly investing (DCA)
What investing the same amount every month would be worth.
Estimate before taxes, fees and currency-conversion costs. Past performance does not guarantee future returns.
Investment growth
Performance
Data for the last 10 years · 2016-07 → 2026-06
Comparison with the market
US$1,000 invested vs S&P 500 ETF (SPY):
- Bristol Myers Squibb (BMY)
- US$1,044
- S&P 500 ETF (SPY)
- US$3,793
Bristol Myers Squibb (BMY) trailed S&P 500 ETF (SPY) over this period.
Risk & drawdowns
The largest peak-to-trough drop in the window was -45.8%. An investor who bought near the prior peak would have seen the investment fall significantly before recovering.
Scenarios
Illustrative results based on the available data.
US$1,000 5 years ago
US$1,016
lump sum, +1.5974555507607402% return
US$100/mo for 5 years
US$6,548
invested US$6,100
If it repeats +0.44%/yr for 10 years
US$1,045
projection from US$1,000 (hypothetical)
About Bristol Myers Squibb (BMY)
Bristol Myers Squibb is one of the large US pharmaceutical companies, especially strong in oncology and cardiovascular disease. Among its most important drugs are Eliquis (a blood thinner sold in partnership with Pfizer), Opdivo (cancer immunotherapy) and, in the past, Revlimid. It scaled up with the 2019 acquisition of Celgene.
It trades on the New York Stock Exchange (NYSE) under the ticker BMY and is part of the S&P 500. It is a dividend stock. Its big challenge is the "patent cliff": several of its best-selling drugs will lose exclusivity over the coming years, so growth depends on launching new products to offset that decline.
Related calculators
Other assets
Frequently asked questions
How much did Bristol Myers Squibb (BMY) return over the last 10 years?
Do these calculations include dividends?
Do they include taxes or fees?
What currency are the values in?
Does past performance predict the future?
Sources & methodology
Prices: Yahoo Finance. Monthly series, total return (dividends reinvested). Data through 2026-06-23.
Total return assumes dividends are reinvested; you can turn that off to see price-only appreciation. Values are estimates before taxes, fees and currency-conversion costs.
Page generated and reviewed by the Calculadora Capital editorial team. Last updated 2026-06-23.